Supplementary Fig. 2. The mean partial Mayo (pMayo) score in patients with different disease activity at baseline and 6 weeks after golimumab treatment (n = 376). Patients with pMayo score were stratified into 3 groups (mild, moderate, and severe) classified by the disease severity at baseline according to the Japanese diagnosis criteria.[1] The mean pMayo score (± standard deviation) at baseline and week 6 was determined in each group.